Investigating strategies to improve AccesS to Kidney transplantation (the ASK trial): a protocol for a feasibility randomised controlled trial with parallel process evaluation.
Feasibility
Kidney transplantation
Nephrology
Randomised controlled trial
Journal
Pilot and feasibility studies
ISSN: 2055-5784
Titre abrégé: Pilot Feasibility Stud
Pays: England
ID NLM: 101676536
Informations de publication
Date de publication:
20 Jan 2023
20 Jan 2023
Historique:
received:
22
11
2021
accepted:
04
01
2023
entrez:
20
1
2023
pubmed:
21
1
2023
medline:
21
1
2023
Statut:
epublish
Résumé
The UK's living-donor kidney transplant (LDKT) activity falls behind that of many other countries internationally, with less than 20% of those eligible receiving a LDKT each year. Certain individuals with kidney disease in the UK appear to be particularly disadvantaged in accessing a LDKT; the most socioeconomically deprived people with kidney disease are 60% less likely to receive a LDKT than the least deprived. Improving equity in living-donor kidney transplantation has been highlighted as an international research priority. This feasibility trial was designed to determine the feasibility of delivery and acceptability of a multicomponent intervention designed to improve access to living-donor kidney transplantation. The intervention comprises three main components: (i) a meeting between a home educator and the transplant candidate for a dedicated discussion about living-donor kidney transplantation, living kidney donation and potential donors; (ii) a standardized letter from a healthcare professional to a candidate's potential donors and (iii) a home-based education and family engagement session including two home educators, the transplant candidate and their family. The primary objectives are to establish the feasibility (i) of delivering the developed intervention in existing care pathways and (ii) of undertaking a randomised controlled trial of the intervention. A mixed-methods parallel process evaluation will investigate the acceptability, implementation and mechanisms of impact of the intervention. The trial is based at two UK hospitals: a transplanting hospital and a non-transplanting referral hospital. Individuals are eligible if they are ≥ 18 years old, are active on the kidney transplant waiting list or have been referred for transplant listing and do not have a potential living-donor undergoing surgical assessment. Randomisation will be undertaken with concealed allocation. Participants will be randomly allocated 1:1 to (i) the intervention or (ii) usual care, stratified by site to ensure a balance in terms of local differences. Minimisation will be used to ensure balance in sex, age group and socioeconomic strata, with probability weighting of 0.8 in order to reduce predictability. The primary outcomes are recruitment (% of those eligible and invited who consent to randomisation) and retention (% of participants completing follow-up). Findings will inform the design of a future fully powered, randomised controlled trial to formally evaluate the effectiveness of the intervention at improving equitable access to living-donor kidney transplantation. ISRCTN Registry ISRCTN10989132 Applied 30/10/20.
Sections du résumé
BACKGROUND
BACKGROUND
The UK's living-donor kidney transplant (LDKT) activity falls behind that of many other countries internationally, with less than 20% of those eligible receiving a LDKT each year. Certain individuals with kidney disease in the UK appear to be particularly disadvantaged in accessing a LDKT; the most socioeconomically deprived people with kidney disease are 60% less likely to receive a LDKT than the least deprived. Improving equity in living-donor kidney transplantation has been highlighted as an international research priority.
METHODS
METHODS
This feasibility trial was designed to determine the feasibility of delivery and acceptability of a multicomponent intervention designed to improve access to living-donor kidney transplantation. The intervention comprises three main components: (i) a meeting between a home educator and the transplant candidate for a dedicated discussion about living-donor kidney transplantation, living kidney donation and potential donors; (ii) a standardized letter from a healthcare professional to a candidate's potential donors and (iii) a home-based education and family engagement session including two home educators, the transplant candidate and their family. The primary objectives are to establish the feasibility (i) of delivering the developed intervention in existing care pathways and (ii) of undertaking a randomised controlled trial of the intervention. A mixed-methods parallel process evaluation will investigate the acceptability, implementation and mechanisms of impact of the intervention. The trial is based at two UK hospitals: a transplanting hospital and a non-transplanting referral hospital. Individuals are eligible if they are ≥ 18 years old, are active on the kidney transplant waiting list or have been referred for transplant listing and do not have a potential living-donor undergoing surgical assessment. Randomisation will be undertaken with concealed allocation. Participants will be randomly allocated 1:1 to (i) the intervention or (ii) usual care, stratified by site to ensure a balance in terms of local differences. Minimisation will be used to ensure balance in sex, age group and socioeconomic strata, with probability weighting of 0.8 in order to reduce predictability. The primary outcomes are recruitment (% of those eligible and invited who consent to randomisation) and retention (% of participants completing follow-up).
DISCUSSION
CONCLUSIONS
Findings will inform the design of a future fully powered, randomised controlled trial to formally evaluate the effectiveness of the intervention at improving equitable access to living-donor kidney transplantation.
TRIAL REGISTRATION
BACKGROUND
ISRCTN Registry ISRCTN10989132 Applied 30/10/20.
Identifiants
pubmed: 36670510
doi: 10.1186/s40814-023-01241-1
pii: 10.1186/s40814-023-01241-1
pmc: PMC9854094
doi:
Types de publication
Journal Article
Langues
eng
Pagination
13Subventions
Organisme : Wellcome Trust
ID : 214554/Z/18/Z
Pays : United Kingdom
Informations de copyright
© 2023. The Author(s).
Références
J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
Psychol Assess. 2014 Jun;26(2):384-94
pubmed: 24320763
Transpl Int. 2013 Dec;26(12):1164-72
pubmed: 24118241
Transplant Direct. 2020 Mar 13;6(4):e540
pubmed: 32309626
Patient Educ Couns. 2014 Jan;94(1):71-5
pubmed: 24169024
Am J Kidney Dis. 2014 Sep;64(3):338-46
pubmed: 24768353
Transplantation. 2012 Mar 27;93(6):610-6
pubmed: 22245879
Transpl Int. 2005 Aug;18(8):975-80
pubmed: 16008749
Clin Transpl. 1995;:363-77
pubmed: 8794280
Transplantation. 2015 Apr;99(4):879-84
pubmed: 25211521
BMJ Open. 2016 Mar 02;6(3):e010605
pubmed: 26936910
Nephrol Dial Transplant. 2017 Feb 1;32(2):216-223
pubmed: 28186535
Kidney Int. 2014 Jul;86(1):162-7
pubmed: 24284516
Health Serv Res. 2004 Aug;39(4 Pt 1):1005-26
pubmed: 15230939
PLoS Med. 2012;9(9):e1001307
pubmed: 22984353
JAMA. 2010 Mar 10;303(10):959-66
pubmed: 20215610
J Epidemiol Community Health. 2006 Jan;60(1):7-12
pubmed: 16361448
Lancet. 1992 Oct 3;340(8823):807-10
pubmed: 1357243
BMC Fam Pract. 2006 Mar 24;7:21
pubmed: 16563164
N Engl J Med. 1995 Aug 10;333(6):333-6
pubmed: 7609748
BMJ. 2016 Oct 24;355:i5239
pubmed: 27777223
BMJ. 2015 Mar 19;350:h1258
pubmed: 25791983
Kidney Int. 1996 Jul;50(1):235-42
pubmed: 8807593
JAMA. 2014 Feb 12;311(6):579-86
pubmed: 24519297
Transplantation. 2016 Nov;100(11):2264-2275
pubmed: 27428715
Int J Qual Health Care. 2007 Dec;19(6):349-57
pubmed: 17872937
Lancet. 2015 May 16;385(9981):2003-13
pubmed: 26090646
Kidney Int. 2019 May;95(5):1244-1252
pubmed: 30952457
J Epidemiol Community Health. 2006 Feb;60(2):95-101
pubmed: 16415256
J Med Internet Res. 2015 Jan 30;17(1):e30
pubmed: 25639757
Ann Transplant. 1996;1(3):32-5
pubmed: 9869917
Can J Urol. 2005 Feb;12(1):2511-20
pubmed: 15777488
J Adv Nurs. 1997 Jan;25(1):95-100
pubmed: 9004016
Health Serv Res. 2005 Dec;40(6 Pt 1):1918-30
pubmed: 16336556
Transplantation. 1999 Mar 15;67(5):717-21
pubmed: 10096528
Clin Transplant. 2020 Apr;34(4):e13830
pubmed: 32072670
Ann Intern Med. 2013 Feb 5;158(3):200-7
pubmed: 23295957
Am J Transplant. 2014 Aug;14(8):1862-9
pubmed: 24935081
Clin Transplant. 2013 Jan-Feb;27(1):9-14
pubmed: 22831164
Nephrol Dial Transplant. 2017 May 01;32(5):890-900
pubmed: 28379431
Transpl Int. 2005 Dec;18(12):1309-17
pubmed: 16297049
Value Health. 2014 Jun;17(4):445-53
pubmed: 24969006
PLoS One. 2021 Jun 25;16(6):e0253667
pubmed: 34170946
Am J Transplant. 2007 Feb;7(2):394-401
pubmed: 17173659